Please Wait.....
Report
Mitsubishi Tanabe Pharma Corporation (4508:TYO) - Strategic SWOT Insights - A 360 Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence and Operational KPI's, and Recent Trends
Company Report I 2025-05-14 I 98 Pages I Quaintel Research
Report Summary
Mitsubishi Tanabe Pharma Corporation - Strategic SWOT Insights - A 360 Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence and Operational KPI's, and Recent Trends is a comprehensive and easily accessible overview of Mitsubishi Tanabe Pharma Corporation 's business operations. It provides a detailed analysis of the company's strategic standing, as well as its position in the industry compared to competitors. The report includes several key features to facilitate decision-making and provide insights into the company's performance.
The report begins with in-depth information about Mitsubishi Tanabe Pharma Corporation including key insights, business segments, key executives, locations, products and services, historical events, corporate strategy, and management discussions. This section provides a solid foundation for understanding the company's key attributes.
Next, the report assesses Mitsubishi Tanabe Pharma Corporation's strategic standing through various analyses. The ESG spotlight evaluates the company's environmental, social, and governance performance, providing insights into its sustainability efforts and ethical practices. The SWOT analysis examines the company's internal strengths and weaknesses, as well as external opportunities and threats. By integrating these strategic analyses, the report offers a comprehensive understanding of Mitsubishi Tanabe Pharma Corporation's overall strategic standing and supports informed decision-making and strategic planning.
Finally, the report includes recent news and deal activities undertaken by Mitsubishi Tanabe Pharma Corporation enhancing awareness of the company's business trends, growth perspectives, and more.
Key Highlights
Mitsubishi Tanabe Pharma Corporation, founded in 1933, is a leading pharmaceutical company specializing in the research, development, manufacturing, and commercialization of innovative medicines. Headquartered in Osaka, Japan, the company operates as a subsidiary of The Mitsubishi Chemical Group and has a strong presence in global markets, including North America, Europe, and Asia. The company focuses on developing high-quality treatments for neurological disorders, autoimmune diseases, kidney diseases, and other medical conditions. In addition to prescription drugs, it offers over-the-counter medications, medical devices, and nutritional supplements, addressing diverse healthcare needs. Mitsubishi Tanabe Pharma is dedicated to improving patient health and well-being through continuous investment in research and development, ensuring the discovery of new, effective treatments. Committed to ethical and responsible business practices, the company prioritizes the safety, efficacy, and quality of its products while contributing to medical advancements worldwide.
Mitsubishi Tanabe Pharma Corporation in the News:-
- 28-Feb-2025 - Regulatory Approval of Cariprazine (MP-214) For Adjunctive therapy for major depressive disorder in Thailand
- 21-Feb-2025 - EMA Accepts Marketing Authorization Application for ND0612, an Investigational Treatment for Motor Fluctuations in Parkinson's Disease
- 17-Feb-2025 - Additional Approval of Dosage Form of CANALIA Combination OD Tablets, Selective DPP-4 inhibitor/SGLT2 inhibitor Combination Drug , First OD Tablets of Selective DPP-4 inhibitor/SGLT2 inhibitor Combination Drug in Japan
- 01-Nov-2024 - Update on U.S. Development Plan of Investigational ND0612 for the Treatment of Motor Fluctuations in People with Parkinson's Disease
- 23-Aug-2024 - Termination of Exclusive Sales Rights Agreements for HGF Gene Therapy Product "Collategene" in Japan and the US
Scope
- Tactical Analysis:- Various strategic frameworks to gain insights into a company's competitive position and operational environment. These analytical tools assist in identifying competitive advantages, potential risks, and areas for improvement and efficiency, enabling companies to make informed tactical decisions.
- Business Strategy:- Contributes to shaping the company's overall direction, goals, and decision-making processes, ensuring long-term success and alignment with stakeholder expectations.
- Company Fundamentals:- These fundamentals offer valuable insights into the company's history, operations, leadership, and geographical presence, aiding in a comprehensive understanding of the organization.
- Competitive Landscape:- An identification of the company's main competitors, providing insights into the competitive landscape it operates in.
Reasons to Buy
- Comprehensive Understanding of the Mitsubishi Tanabe Pharma Corporation's internal and external factors through SWOT analysis and Corporate Strategy.
- Strive Strategic Decision Making with various analyses and identifying potential customers and suppliers.
- Mitigate Risk with help of thorough analysis of internal and external factors. Furthermore, develop strategies and contingency plans to address these challenges and minimize their impact on business operations.
- Competitive Benchmarking will help to gain a competitive advantage by understanding industry trends, customer preferences, and best practices.
- Valuable insights from the report enable investors and partners to make informed decisions regarding potential Collaborations, Investments, or Partnerships with the company.
Additionally, available deep-dive analysis on the company Mitsubishi Tanabe Pharma Corporation:
- Mitsubishi Tanabe Pharma Corporation PESTLE Analysis
- Mitsubishi Tanabe Pharma Corporation Value Chain Analysis
- Mitsubishi Tanabe Pharma Corporation Porter's Five Forces Analysis
- Mitsubishi Tanabe Pharma Corporation VRIO Analysis
- Mitsubishi Tanabe Pharma Corporation BCG Analysis
- Mitsubishi Tanabe Pharma Corporation Segmentation, Targeting and Positioning (STP) Analysis
- Mitsubishi Tanabe Pharma Corporation Ansoff Matrix Analysis
Table of Contents
Table of Contents 2
Tables 5
Charts 6
Mitsubishi Tanabe Pharma Corporation - Key Company Facts 7
Mitsubishi Tanabe Pharma Corporation - Company Description 8
Mitsubishi Tanabe Pharma Corporation - Top Executives 9
Mitsubishi Tanabe Pharma Corporation - Head Office & Locations 10
Head Office - Country 10
Mitsubishi Tanabe Pharma Corporation - Products and Services 11
Products 11
Services 12
Mitsubishi Tanabe Pharma Corporation - Corporate Strategy 13
Mitsubishi Tanabe Pharma Corporation - Business Description 17
Prescription Pharmaceuticals 18
Over the Counter Medications and Consumer Healthcare 18
Medical Devices and Diagnostics 18
Contract Manufacturing and Licensing 19
Nutritional Supplements and Health Products 19
Mitsubishi Tanabe Pharma Corporation - ESG Spotlight 20
Environment 20
Social 21
Corporate Governance 21
Mitsubishi Tanabe Pharma Corporation - SWOT Analysis 23
Overview 23
Strengths 25
Weaknesses 28
Opportunities 29
Threats 32
Competing Players 33
Snapshot of Competing Players 34
Astellas Pharma Inc. 34
Key Company Facts 34
Company Description 34
Astellas Pharma Inc. - SWOT Spotlight 35
Astellas Pharma Inc. - PESTLE Spotlight 37
Key Financials 39
Share Price Trend - Jan-2024 to May-2025 (Average Share Closing Price) 39
Key Financial Ratio Analysis 44
Daiichi Sankyo Company Limited 45
Key Company Facts 45
Company Description 45
Daiichi Sankyo Company Limited - SWOT Spotlight 46
Daiichi Sankyo Company Limited - PESTLE Spotlight 48
Key Financials 50
Share Price Trend - Jan-2024 to May-2025 (Average Share Closing Price) 50
Key Financial Ratio Analysis 55
Eisai Co Ltd 56
Key Company Facts 56
Company Description 56
Key Financials 57
Share Price Trend - Jan-2024 to May-2025 (Average Share Closing Price) 57
Key Financial Ratio Analysis 62
Kobayashi Pharmaceutical Co Ltd 63
Key Company Facts 63
Company Description 63
Key Financials 64
Share Price Trend - Jan-2024 to May-2025 (Average Share Closing Price) 64
Key Financial Ratio Analysis 69
Takeda Pharmaceutical Company Limited 70
Key Company Facts 70
Company Description 70
Takeda Pharmaceutical Company Limited - SWOT Spotlight 71
Takeda Pharmaceutical Company Limited - PESTLE Spotlight 73
Key Financials 75
Share Price Trend - Jan-2024 to May-2025 (Average Share Closing Price) 75
Key Financial Ratio Analysis 80
Mitsubishi Tanabe Pharma Corporation - In the News 81
28-Feb-2025 - Regulatory Approval of Cariprazine (MP-214) For Adjunctive therapy for major depressive disorder in Thailand 81
21-Feb-2025 - EMA Accepts Marketing Authorization Application for ND0612, an Investigational Treatment for Motor Fluctuations in Parkinson's Disease 82
17-Feb-2025 - Additional Approval of Dosage Form of CANALIA Combination OD Tablets, Selective DPP-4 inhibitor/SGLT2 inhibitor Combination Drug , First OD Tablets of Selective DPP-4 inhibitor/SGLT2 inhibitor Combination Drug in Japan 83
01-Nov-2024 - Update on U.S. Development Plan of Investigational ND0612 for the Treatment of Motor Fluctuations in People with Parkinson's Disease 84
23-Aug-2024 - Termination of Exclusive Sales Rights Agreements for HGF Gene Therapy Product "Collategene" in Japan and the US 85
04-Mar-2024 - Expiration of Marketing Alliance Agreement for TENELIA Tablets, TENELIA OD Tablets and CANAGLU Tablets 86
27-Jan-2024 - Announcement of Organizational Changes and Personnel Changes of the Mitsubishi Chemical Group 87
27-Jan-2024 - Launch of Radicava for the Treatment of ALS in Brazil 88
26-Jan-2024 - Mitsubishi Tanabe Pharma contribute funding to Global Health Innovative Technology Fund's third phase ?Targeting treatments for infectious diseases that burden the developing world 89
23-Jan-2024 - Co-promotion of "GOBIK Aqueous Suspension Syringes", Pertussis, Diphtheria, Tetanus, Inactivated Polio and Hib Combined Vaccine 90
Mitsubishi Tanabe Pharma Corporation - Key Deals 92
07-Jan-2025 - Sub-licensing Agreement for the Oral Spleen Tyrosine Inhibitor Fostamatinib in Taiwan with Kissei Pharmaceutical 92
05-Dec-2024 - Mitsubishi Tanabe Pharma Corporation Entered into Research Collaboration with Dewpoint to Advance Small Molecule Condensate Modulator for ALS 93
08-Jul-2024 - Moderna And Mitsubishi Tanabe Pharma Corporation Enter Joint Agreement to Promote Moderna's mRNA Respiratory Vaccine Portfolio in Japan, Including COVID-19 Vaccines 94
Appendix 95
Definitions 95
SWOT Analysis 95
PESTLE Analysis 95
Value Chain Analysis 95
ESG Spotlight 95
Research Methodology 96
Disclaimer 97
Contact Us 97
Tables
Table 1: Mitsubishi Tanabe Pharma Corporation - Company Facts
Table 2: Mitsubishi Tanabe Pharma Corporation - Digital Presence
Table 3: Mitsubishi Tanabe Pharma Corporation - Top Executives
Table 4: Mitsubishi Tanabe Pharma Corporation - Products
Table 5: Mitsubishi Tanabe Pharma Corporation - Services
Table 6: Mitsubishi Tanabe Pharma Corporation - Competing Players
Table 7: Competing Players - Astellas Pharma Inc. - Key Company Facts
Table 8: Astellas Pharma Inc. - Share Price Trend - Jan-2024 to May-2025
Table 9: Competing Players - Astellas Pharma Inc. - Profit and Loss Statement
Table 10: Astellas Pharma Inc. - Balance Sheet 2021-2024
Table 11: Astellas Pharma Inc. - Cash Flow Statement 2021-2024
Table 12: Astellas Pharma Inc. - Ratio Analysis - 2021-2024
Table 13: Competing Players - Daiichi Sankyo Company Limited - Key Company Facts
Table 14: Daiichi Sankyo Company Limited - Share Price Trend - Jan-2024 to May-2025
Table 15: Competing Players - Daiichi Sankyo Company Limited - Profit and Loss Statement
Table 16: Daiichi Sankyo Company Limited - Balance Sheet 2021-2024
Table 17: Daiichi Sankyo Company Limited - Cash Flow Statement 2021-2024
Table 18: Daiichi Sankyo Company Limited - Ratio Analysis - 2021-2024
Table 19: Competing Players - Eisai Co Ltd - Key Company Facts
Table 20: Eisai Co Ltd - Share Price Trend - Jan-2024 to May-2025
Table 21: Competing Players - Eisai Co Ltd - Profit and Loss Statement
Table 22: Eisai Co Ltd - Balance Sheet 2021-2024
Table 23: Eisai Co Ltd - Cash Flow Statement 2021-2024
Table 24: Eisai Co Ltd - Ratio Analysis - 2021-2024
Table 25: Competing Players - Kobayashi Pharmaceutical Co Ltd - Key Company Facts
Table 26: Kobayashi Pharmaceutical Co Ltd - Share Price Trend - Jan-2024 to May-2025
Table 27: Competing Players - Kobayashi Pharmaceutical Co Ltd - Profit and Loss Statement
Table 28: Kobayashi Pharmaceutical Co Ltd - Balance Sheet 2020-2023
Table 29: Kobayashi Pharmaceutical Co Ltd - Cash Flow Statement 2020-2023
Table 30: Kobayashi Pharmaceutical Co Ltd - Ratio Analysis - 2020-2023
Table 31: Competing Players - Takeda Pharmaceutical Company Limited - Key Company Facts
Table 32: Takeda Pharmaceutical Company Limited - Share Price Trend - Jan-2024 to May-2025
Table 33: Competing Players - Takeda Pharmaceutical Company Limited - Profit and Loss Statement
Table 34: Takeda Pharmaceutical Company Limited - Balance Sheet 2021-2024
Table 35: Takeda Pharmaceutical Company Limited - Cash Flow Statement 2021-2024
Table 36: Takeda Pharmaceutical Company Limited - Ratio Analysis - 2021-2024
Charts
Figure 1: Mitsubishi Tanabe Pharma Corporation - SWOT Analysis
Figure 2: Competing Players - Astellas Pharma Inc. - SWOT Spotlight
Figure 3: Competing Players - Astellas Pharma Inc. - PESTLE Spotlight
Figure 4: Astellas Pharma Inc. - Average Share Price Trend - Jan-2024 to May-2025
Figure 5: Astellas Pharma Inc. - Profit and Loss Statement - 2021-2024
Figure 6: Astellas Pharma Inc. - Balance Sheet - 2021-2024
Figure 7: Astellas Pharma Inc. - Cash Flow Statement 2021-2024
Figure 8: Competing Players - Daiichi Sankyo Company Limited - SWOT Spotlight
Figure 9: Competing Players - Daiichi Sankyo Company Limited - PESTLE Spotlight
Figure 10: Daiichi Sankyo Company Limited - Average Share Price Trend - Jan-2024 to May-2025
Figure 11: Daiichi Sankyo Company Limited - Profit and Loss Statement - 2021-2024
Figure 12: Daiichi Sankyo Company Limited - Balance Sheet - 2021-2024
Figure 13: Daiichi Sankyo Company Limited - Cash Flow Statement 2021-2024
Figure 14: Eisai Co Ltd - Average Share Price Trend - Jan-2024 to May-2025
Figure 15: Eisai Co Ltd - Profit and Loss Statement - 2021-2024
Figure 16: Eisai Co Ltd - Balance Sheet - 2021-2024
Figure 17: Eisai Co Ltd - Cash Flow Statement 2021-2024
Figure 18: Kobayashi Pharmaceutical Co Ltd - Average Share Price Trend - Jan-2024 to May-2025
Figure 19: Kobayashi Pharmaceutical Co Ltd - Profit and Loss Statement - 2020-2023
Figure 20: Kobayashi Pharmaceutical Co Ltd - Balance Sheet - 2020-2023
Figure 21: Kobayashi Pharmaceutical Co Ltd - Cash Flow Statement 2020-2023
Figure 22: Competing Players - Takeda Pharmaceutical Company Limited - SWOT Spotlight
Figure 23: Competing Players - Takeda Pharmaceutical Company Limited - PESTLE Spotlight
Figure 24: Takeda Pharmaceutical Company Limited - Average Share Price Trend - Jan-2024 to May-2025
Figure 25: Takeda Pharmaceutical Company Limited - Profit and Loss Statement - 2021-2024
Figure 26: Takeda Pharmaceutical Company Limited - Balance Sheet - 2021-2024
Figure 27: Takeda Pharmaceutical Company Limited - Cash Flow Statement 2021-2024
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security